Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO1991001753) INHIBITION OF TUMOR GROWTH BY BLOCKADE OF THE PROTEIN C SYSTEM
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1991/001753 International Application No.: PCT/US1990/004337
Publication Date: 21.02.1991 International Filing Date: 02.08.1990
Chapter 2 Demand Filed: 28.02.1991
IPC:
A61K 38/00 (2006.01) ,A61K 38/48 (2006.01) ,A61K 39/395 (2006.01) ,C07K 14/47 (2006.01) ,C07K 14/745 (2006.01) ,C07K 16/36 (2006.01) ,C07K 16/40 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43
Enzymes; Proenzymes; Derivatives thereof
46
Hydrolases (3)
48
acting on peptide bonds (3.4)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
46
from vertebrates
47
from mammals
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
745
Blood coagulation or fibrinolysis factors
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
36
against blood coagulation factors
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
40
against enzymes
Applicants:
OKLAHOMA MEDICAL RESEARCH FOUNDATION [US/US]; 825 N.E. Thirteenth Oklahoma City, OK 73104, US
Inventors:
ESMON, Charles, T.; US
COMP, Philip, C.; US
Agent:
PABST, Patrea, L. ; Kilpatrick & Cody 100 Peachtree Street Suite 3100 Atlanta, GA 30303, US
Priority Data:
389,61704.08.1989US
Title (EN) INHIBITION OF TUMOR GROWTH BY BLOCKADE OF THE PROTEIN C SYSTEM
(FR) INHIBITION DE LA CROISSANCE TUMORALE PAR BLOCAGE DU SYSTEME DE PROTEINE C
Abstract:
(EN) Compositions, and methods of use thereof, for the inhibition of tumor growth and killing of tumors having extensive microcirculation wherein the active agent is a compound blocking the protein C system, preferably anti-protein C antibody, anti-protein S antibody and C4b binding protein. In the most preferred embodiment, the protein C blocking compound is provided in combination with a cytokine such as tumor necrosis factor (TNF), gamma interferon, interleukin-1, interleukin-2 and granulocyte-macrophage colony stimulating factor. Examples are provided demonstrating the administraion of the protein C blocking compound, alone or in combination with TNF, to dogs having canine venereal tumors, a fibrosarcoma, and an adenocarcinoma, to pigs with melanoma, and a primate with a malignant lymphoma, followed by significant tumor reduction.
(FR) Des compositions et leurs procédés d'utilisation permettent d'inhiber la croissance tumorale et de détruire des tumeurs a microcirculation étendue. L'agent actif est un composé qui bloque le système de protéine C, de préférence un anticorps de l'anti-protéine C, un anticorps de l'anti-protéine S et une protéine de liaison de C4b. Dans le mode préférentiel de réalisation, le composé de blocage de la protéine C est associé à une cytokine telle que le facteur de nécrose de tumeurs (TNF), l'interféron gamma, l'interleucine-1, l'interleucine-2 et le facteur de stimulation des colonies de granulocytes-macrophages. On décrit des exemples d'administration du composé de blocage de la protéine C, que ce soit isolément ou en association avec TNF, à des chiens ayant des tumeurs vénériennes canines, un fibrosarcome, et un adénocarcinome, à des cochons ayant des mélanomes, et à un primate avec un lymphome malin, l'administration du composé ayant été suivie d'une réduction significative des tumeurs.
Designated States: AU, CA, JP
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP0489048JP7029937CA2064585AU1990061643